ASCLS eNewsBytes

• Study Explores Methods to Enhance Cancer-Gene Testing in Clinics March 10, 2025
  A study by Dr. Elizabeth Swisher and colleagues found that up to 10% of cancers are caused by genes easily detected by commercially available tests. The study suggests two ways primary-care practices could assess patients' hereditary cancer risks and deliver testing to those identified as higher risk.
• FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL March 10, 2025
  Adcetris®, a combination of lenalidomide and rituximab, has been approved by the FDA for treating relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), a common and difficult-to-treat form of lymphoma.
• Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment March 10, 2025
  Immunotherapy approaches in triple-negative breast cancer have led to breakthroughs using immune checkpoint inhibitors. Researchers are exploring immunotherapy in combination with existing treatment modalities, such as pembrolizumab and SPARK.
• FDA Approves Neffy 1 MG Nasal Spray for Pediatric Patients March 10, 2025
  The FDA has approved ARS Pharmaceuticals' neffy 1mg for treating Type 1 allergic reactions in pediatric patients aged four and above. Neffy is the first significant innovation for this population in over 35 years, addressing the concern of 56% of caregivers about injecting their child.
• Could CRISPR Help Prevent the Next Global Pandemic? March 10, 2025
  CRISPR-CRISPR-associated systems, developed in bacteria, function as a microbial immune system to detect and defend against viral infections. They have been adapted for biomedical applications, including rapid pathogen detection and targeted gene modifications.